Zydus to expand vaccine capacity
Zydus Cadila seeks to produce 150 million doses of its covid vaccine ZyCoV-D annually
(MINT PRINT)Premium
The company has invested ₹250-350 crore so far on trials of the vaccine and its manufacturing
Zydus Cadila expects to submit to the drug regulator its safety and efficacy data for the vaccine in either April or June
Share Via
Read Full Story
Zydus Cadila Ltd will expand capacity of its covid-19 vaccine ZyCoV-D to produce 150 million doses a year and hire contract manufacturers to make an additional 50 to 70 million doses, a company spokesperson said.
“We have been investing a large amount of our capacities in building the vaccine, so we will now be able to produce 150 million doses of the vaccine annually, the spokesperson said, adding that the vaccine will be produced at its Zydus Biotech Park plant in Ahmedabad.
Zydus Cadila Covid-19 Vaccine Gets DCGI Approval For Phase-3 Trials
ZyCoV-D was found to be safe, well-tolerated and immunogenic in phase I and II clinical trials, the company said.
PTI 03 January 2021 PTI outlookindia.com 2021-01-03T18:24:21+05:30
Also read
The Drugs Controller General of India (DCGI) has approved conducting phase III trials of the country s first DNA vaccine candidate against Covid-19 being developed by Zydus Cadila, the Department of Biotechnology said on Sunday.
The vaccine candidate has been supported by the National Biopharma Mission (NBM) under the aegis of Biotechnology Industry Research Assistance Council (BIRAC), a PSU under the DBT.